← boardnext 2026-09next 2026-10
BHVN
Biohaven Therapeutics Ltd.distress 6/10 · elevated risk$14.49-2%today-20% from 52w high
Psychiatry / CNS 4Neurology 2Oncology 1
Lead: Focal Epilepsy · target Kv7
Revenue
pre-revenue
Liquidity
$348M
Runway
0.6 yrs
Shares 1y
+42%
Price & events
+5.3% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.7%
1D
+2.3%
1W
-1.9%
1M
+37.8%
3M
+7.3%
6M
+5.5%
1Y
-61.7%
2Y
—
5Y
+103.1%
All
Overview
- Market Cap
- $2.18B
- Volume
- 100.44K
- 52 Week Range
- $7.79 – $18.11
- Total Shares
- 150.56M
- Float Shares
- 123.75M
- Short %
- 17.41%
- % Held by Insiders
- 11.08%
- % Held by Institutions
- 91.58%
- RVOL
- 0.03x
- Beta
- 3.14
Pipeline stages · 4 programs
Taldefgrobep Alfa
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
BHV-1530
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Troriluzole (BHV-4157)Glutamate
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
BHV-1100 plus cytokine induced memory-like (CIML) NK cells plus IVIG and low dose IL-2
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 19 trials · 9 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-09 Estimated 50% readout ~2026-10-16 | Phase 2 | Taldefgrobep Alfa | Obesity, Overweight | — | active not recruiting |
| 2026-10 Estimated 50% readout ~2026-12-15 | Phase 2/3 | BHV-7000 | Focal Epilepsy | — | active not recruiting |
| 2026-12 Estimated 50% readout ~2027-02-14 | Phase 2/3 | BHV-7000 | Focal Epilepsy | — | recruiting |
| 2026-12 Estimated 50% readout ~2027-01-15 | Phase 2 | BHV-7000 | Focal Epilepsy | — | enrolling by invitation |
| 2027-08 Estimated 50% readout ~2027-10-15 | Phase 2/3 | BHV-8000 | Parkinson Disease | — | recruiting |
Show all 19 trials · 14 more ▾
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2028-01 Estimated 50% readout ~2028-03-16 | Phase 3 | BHV-1300 | Graves Disease | — | recruiting |
| 2028-02 Estimated 50% readout ~2028-03-17 | Phase 1/2 | BHV-1510, Cemiplimab | Solid Tumor | — | recruiting |
| 2028-09 Estimated 50% readout ~2028-11-15 | Phase 3 | BHV-1400 | IgA Nephropathy | — | not yet recruiting |
| 2029-03 Estimated 50% readout ~2029-03-31 | Phase 1 | BHV-1530 | Solid Tumor | — | recruiting |
| 2026-03-18 | Phase 2 | BHV-7000 | Major Depressive Disorder | 233 | completed |
| 2026-03-12 | Phase 2/3 | BHV-7000 | Generalized Epilepsy | 27 | terminated |
| 2026-02-13 | Phase 3 | Troriluzole (BHV-4157)fast trackorphan | Obsessive Compulsive Disorder | 772 | terminated |
| 2025-11-07 | Phase 2 | BHV-7000 | Major Depressive Disorder | 336 | completed |
| 2025-10-27 | Phase 3 | Troriluzolefast trackorphan | Obsessive-Compulsive Disorder | 456 | completed |
| 2025-04-29 | Phase 3 | Troriluzolefast trackorphan | Obsessive-Compulsive Disorder | 589 | completed |
| 2025-04-25 | Phase 2 | BHV-7000 | Bipolar Disorder | 94 | terminated |
| 2025-03-24 | Phase 2 | BHV-2100 | Migraine | 647 | completed |
| 2025-01-15 | Phase 2/3 | BHV-7000 | Bipolar Disorder | 274 | completed |
| 2025-01-10 | Phase 1 | BHV-1100 plus cytokine induced memory-like (CIML) NK cells plus IVIG and low dose IL-2 | Multiple Myeloma | 7 | completed |
Catalyst news & presentations · 4
- 2026-08-10earningsEarningsEarnings releaseyahoo
- fourth quarter of 2025PDUFAPDUFAtroriluzole · New PDUFA target date for NDA decisionSEC 8-K
- 2025-05-14pdufa extensiontroriluzole · PDUFA date extended by three months to Q4 2025SEC 8-K
- fourth quarter of 2024regulatory submissionFiled (NDA/BLA)troriluzole · Plan to submit NDA to FDASEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
buy · target $23 (+57% upside) · 16 analysts
- 2026-06-29B of A SecuritiesNeutral → Underperform
- 2026-05-26HC Wainwright & Co.Neutral
- 2026-05-13Morgan StanleyOverweight
- 2026-05-05RBC CapitalOutperform
- 2026-04-02CitigroupBuy
- 2026-03-11TD CowenBuy
Competitors — Kv7
- XENEXenon Pharmaceuticals Inc.$6.3B · D3
Recent news
- 2026-07-20Biohaven to Present New Clinical Data at ESMO Congress on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload - StreetInsider
- 2026-07-20Biohaven to Present New Clinical Data at ESMO Congress on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload - PR Newswire
- 2026-07-18Biohaven Presents Data Across Innovative Neuroscience Portfolio - GuruFocus
- 2026-07-18How Biohaven’s (BHVN) R&D Leadership Shuffle Will Impact Investors - simplywall.st
- 2026-07-17Lobbying Update: $120,000 of BIOHAVEN LTD. lobbying was just disclosed - Quiver Quantitative
- 2026-07-17Price to book forward of Biohaven Ltd. – NYSE:BHVN - TradingView
- 2026-07-17Discipline and Rules-Based Execution in BHVN Response - Stock Traders Daily
- 2026-07-17Biohaven files Form 3 for Chief Legal Officer Warren Karl Volles - Bitget
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.